Cantor Fitzgerald Reiterates “$103.00” Price Target for Spark Therapeutics (ONCE)

Spark Therapeutics (NASDAQ:ONCE) has been assigned a $103.00 price target by research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 157.24% from the company’s previous close.

A number of other research firms have also weighed in on ONCE. ValuEngine lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. UBS Group decreased their target price on shares of Spark Therapeutics from $80.00 to $53.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 8th. William Blair reissued a “buy” rating on shares of Spark Therapeutics in a research note on Friday, September 21st. Raymond James set a $82.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Finally, Mizuho reissued a “buy” rating and issued a $77.00 target price on shares of Spark Therapeutics in a research note on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $70.10.

Spark Therapeutics stock traded down $3.98 during midday trading on Tuesday, reaching $40.04. The company had a trading volume of 5,579 shares, compared to its average volume of 497,808. The firm has a market capitalization of $1.70 billion, a PE ratio of -5.25 and a beta of 2.27. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.34). Spark Therapeutics had a negative return on equity of 17.33% and a negative net margin of 185.46%. The business had revenue of $25.19 million during the quarter, compared to analysts’ expectations of $29.44 million. On average, equities analysts anticipate that Spark Therapeutics will post -1.44 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. C WorldWide Group Holding A S increased its holdings in shares of Spark Therapeutics by 6.6% during the 3rd quarter. C WorldWide Group Holding A S now owns 54,999 shares of the biotechnology company’s stock worth $3,000,000 after buying an additional 3,403 shares during the last quarter. Smith Asset Management Group LP increased its holdings in shares of Spark Therapeutics by 39.6% during the 3rd quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock worth $215,000 after buying an additional 1,120 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of Spark Therapeutics by 34.2% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 476,121 shares of the biotechnology company’s stock worth $25,972,000 after buying an additional 121,438 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Spark Therapeutics during the 3rd quarter worth approximately $122,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of Spark Therapeutics by 22.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 24,459 shares of the biotechnology company’s stock worth $1,335,000 after buying an additional 4,438 shares during the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Further Reading: Trading Penny Stocks

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply